Navigation Links
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Date:1/6/2009

NOVATO, Calif. and SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that they have entered into an agreement to develop and commercialize Riquent(R), La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Following a successful Phase 3 trial, the parties will share equally in all losses and profits. In the United States, BioMarin and La Jolla will jointly commercialize Riquent. In Europe and other territories outside of Asia, BioMarin will be responsible for all commercialization activities.

Jean-Jacques Bienaime, Chief Executive Officer of BioMarin commented, "We are very pleased to become La Jolla Pharmaceutical's partner for Riquent. The development history of Riquent has been long and challenging, but we feel the current study addresses the shortcomings of prior studies and provides the best possible opportunity to demonstrate that Riquent reduces the frequency of renal flares in lupus nephritis patients. The ASPEN Phase 3 study is the largest clinical study ever conducted in lupus nephritis and there is increasing evidence that Riquent targets one of the most important underlying causes of kidney disease in lupus patients, antibodies to double stranded DNA.

Mr. Bienaime continued, "This product opportunity also represents an exceptionally good strategic fit for BioMarin. Lupus nephritis is a serious and potentially fatal orphan disease treated by specialists, primarily nephrologists and rheumatologists, and there are no products specifically approved to treat lupus renal disease. Importantly, if the ASPEN stud
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.; La Jolla Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. Pfizer Closes La Jolla Campus Due to Continuing Fire Emergency
10. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... The Latin American poultry feed and feed ... and forecast of revenue. The poultry feed and feed additive ... million and $647.2 million in 2013 to $34,024.0 million and ... 2013 to 2018, respectively. , To get an idea of ... of the Latin American poultry feed and feed additive market ...
(Date:7/29/2014)... UT (PRWEB) July 29, 2014 Frank ... produce powders can help parents add nutrition to their ... “Little Bites – Key market drivers in kids’ foods ... Nutrition, is pleased to announce the interview Frank Davis ... adding the Activz organic vegetable and fruit produce powders ...
(Date:7/29/2014)... News) -- Decorative contact lenses may seem like a ... cause serious eye damage. Decorative contacts should be ... the U.S. Food and Drug Administration (FDA). It,s important ... for these lenses and buy them from a trustworthy ... about the potential health risks associated with decorative contact ...
(Date:7/29/2014)... State College of Medicine, have jointly received nearly ... data research network., The Patient-Centered Outcomes Research Institute ... and Affordable Care Act, awarded the funds to ... Johns Hopkins University -- and each of their ... together to create a Clinical Data Research Network, ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 July 29, 2014 ... home care, is proud to announce that it is a ... inspiring online video segments; Silverado Through a Child's Eye ... , In Silverado Through a Child's Eye , ... her mom at Silverado Beverly Place, a memory care community ...
Breaking Medicine News(10 mins):Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 2Health News:Activz Organic Fruit and Vegetable Produce Powders and Founder Frank Davis Mentioned in WholeFoods Magazine Article 3Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:New network unites university health care research 2Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2
... a tree affords complete protection from the sun, say researchers ... to sit under a tree and assume that the foliage ... the shade for granted, say researchers at Purdue University in ... reveals just how much protecting from harmful ultraviolet B light ...
... a hormone called Leptin, produced by fat cells, could ... at the University of Hopkins said obese people have ... relationship between obesity and clotting risk is not well ... Dr. Daniel T. Eitzman, a cardiologist and assistant professor ...
... Lyme disease linger despite antibiotic treatment.,Lyme disease, caused by ... very long-lasting fatigue and cognitive problems. Even though antibiotic ... treatment would not be enough to clear up the ... of whom were assigned to the antibiotic ceftriaxone while ...
... should not assume sneezing and watery eyes are always due ... months, you may well assume it's a pollen allergy starting ... or diagnosis might be pollen allergy.// ,Doctors at the ... rhinitis. Here the inner lining of the nose is just ...
... the risk of heart disease. Researchers found that women over ... risk of dying from heart disease. Low levels of certain ... of heart attacks.// ,But the positive impact of taking ... and calcium are part of the standard therapy for the ...
... program can accurately diagnose a heart attack even when some ... of more than 1,000 adults who went to the emergency ... 80% of people who were having a heart attack.// ... to rely on the computer program to diagnose patients with ...
Cached Medicine News:Health News:Computer Program can assist to detect Heart Attack 2
(Date:7/29/2014)... , July 29, 2014  Synthetic Biologics, Inc. (NYSE ... drug candidates targeting specific pathogens that cause serious infections ... unusual market activity in the Company,s stock, the NYSE ... with its usual practice. The Company stated that its ... About Synthetic Biologics, Inc. Synthetic ...
(Date:7/29/2014)... New high priced hepatitis C drugs will ... projected $2.9 to $5.8 billion next year, according to ... today by the Pharmaceutical Care Management Association (PCMA). Milliman ... as much as 8.6 percent in 2015 as a ... Olysio. The study finds that the majority ...
(Date:7/29/2014)... 29, 2014 According to a ... Navigation Systems Market (Neurosurgical Navigation Systems, ENT Navigation Systems ... Share, Growth, Trends and Forecast, 2014 - 2020", the ... 218.5 million in 2013 and is expected to grow ... to reach an estimated value of USD 295.5 million ...
Breaking Medicine Technology:Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... Oct. 5 The Thompson Group of Companies announced ... (AIT), a Hamilton Sundstrand Corporation business. AIT will ... Group. Financial terms of the purchase were not disclosed. ... manufacture and marketing of process analytical instruments including Analect ...
... CITY, Oct. 5 Orthopedics This Week , a ... Awards for Best New Technology for Spine Care in ... implant and instrument manufacturer focused on unique silicon nitride (SiN) ... in Biomaterials category for its Valeo® AL Lumbar Spacer ...
Cached Medicine Technology:Thompson Group Acquires Hamilton Sundstrand's Applied Instrument Technologies 2Two Amedica®/US Spine® Implant Products Receive Best New Technology Awards from Orthopedics This Week 2
For primary and revision cases...
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Performa cemented stem....
Medicine Products: